Oxford Nanopore Technologies reported a 26% year-over-year revenue increase for the first half of 2025, reaching £105.6 million ($141.3 million). Drivers include a 53% increase in instrument sales and over 45% growth in clinical market revenues, especially in oncology and rare disease testing. The company is increasing its focus on high-throughput PromethIon platforms while managing costs and workforce rationalization to support prioritized growth initiatives.